81479-48-3

Basic information

• Product Name: (5-tert-butyl-isoxazol-3-yl)-carbaMic acid phenyl ester, (5-tert-butylisoxazol-3-yl)carbaMic acid phenyl ester
• Synonyms: (5-tert-butyl-isoxazol-3-yl)-carbaMic acid phenyl ester, (5-tert-butylisoxazol-3-yl)carbaMic acid phenyl ester;phenyl (5-(tert-butyl)isoxazol-3-yl)carbamate;Carbamic acid,N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-, phenyl ester;Phenyl N-(5-tert-butyl-1,2-oxazol-3-yl)carbamate
• CAS NO: 81479-48-3
• Molecular Formula: C₁₄H₁₆N₂O₃
• Molecular Weight: 260.28844
• Mol File: 81479-48-3.mol

Chemical Properties

• Boiling Point: 362.9±34.0 °C(Predicted)
• Appearance: /
• Density: 1.198±0.06 g/cm3(Predicted)
• PKA: 11.38±0.70(Predicted)
• CAS DataBase Reference: (5-tert-butyl-isoxazol-3-yl)-carbaMic acid phenyl ester, (5-tert-butylisoxazol-3-yl)carbaMic acid phenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (5-tert-butyl-isoxazol-3-yl)-carbaMic acid phenyl ester, (5-tert-butylisoxazol-3-yl)carbaMic acid phenyl ester(81479-48-3)
• EPA Substance Registry System: (5-tert-butyl-isoxazol-3-yl)-carbaMic acid phenyl ester, (5-tert-butylisoxazol-3-yl)carbaMic acid phenyl ester(81479-48-3)

Safety Data

• Hazardous Substances Data: 81479-48-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
(5-tert-butyl-isoxazol-3-yl)-carbamic acid phenyl ester and (5-tert-butylisoxazol-3-yl)carbamic acid phenyl ester are used as building blocks in organic chemistry for the synthesis of various pharmaceutical drugs. They are also used as research tools in the study of biological pathways and drug interactions.
Used in Medicinal Chemistry and Drug Discovery:
These compounds play an important role in the field of medicinal chemistry and drug discovery, contributing to the development of new therapeutic agents and enhancing our understanding of disease mechanisms.

Upstream product

• 55809-36-4 3-amino-5-tert-butylisoxazole 
• 1885-14-9 phenyl chloroformate 

Relevant articles and documents

NEW THERAPEUTIC AGENTS FOR THE TREATMENT OF HAEMATOLOGICAL PATHOLOGIES

The present invention relates to compounds having a tetracyclic system and the use thereof as new therapeutic agents in the treatment of acute myeloid leukemia (AML), preferably in FLT3/ITD hemizygote patients resistant to conventional therapies. The invention also relates to 5,7-dihydro-4H-[1,3]thiazolo[4,5-e]isoindol-2-amine compounds useful as intermediates for the synthesis of tetracyclic imidazo[2',1':2,3][1,3]thiazolo[4,5-e]isoindole compounds.

5-6 -dihydrobenzo [h] quinazoline compound and application thereof

The invention discloses 5-6 -dihydrobenzo [h] quinazoline compound and application thereof, and belongs to the field of medicines. I, 5-dihydrobenzo [6 -] quinazoline compounds represented by the formula h of the invention have excellent inhibition FLT3 i

Synthesis and biological evaluation of novel 5,6-dihydrobenzo[h]quinazoline derivatives as FLT3 inhibitors

Fms-like tyrosine kinase 3 (FLT3) is widely expressed and often mutated in acute myeloid leukemia (AML), which makes it an important target for the treatment of AML. The structure-based synthesis and biological evaluation of 5,6-dihydrobenzo[h]quinazoline

Inhibitors of NEK7 kinase

Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I):or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein, A, X, Y, R1, R2, R3, R4 and R5 are as defined herein. Methods associated with p

Benzo imidazo [2, 1-b] thiazole compound and application thereof (by machine translation)

The invention discloses a benzoimidazo [2, 1-b] thiazole compound and application thereof, and belongs to the technical field of medicines. The inhibitory activity of the synthesized benzimidazo [2, 1-b] thiazole analogues on FLTT3 is more than 90%, wherein the compounds (compounds 2 , 4, 6, 8 and 10) are IC of FLTT3-ITD kinase. 50 Lower value, in particular compound 2, IC IC50 The value is only 5.60 nm, and therefore the compound of the present invention may be used as an inhibitor FLTT3, or for preparing a drug capable of modulating or suppressing diseases associated with abnormal cell proliferation by affecting the enzymatic activity of one or more tyrosine kinases and interfering with aberrant cell proliferation, having a wide application prospect. (by machine translation)

Synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors

As a class III receptor tyrosine kinase (RTK), FMS-like tyrosine kinase 3 (FLT3) is always overexpressed in many cases of acute leukemia. This paper studies the structure-based synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors. Encouragingly, compounds 15b, 16b, 24a, and 24c showed excellent biological activities in a low nanomolar range. In particular, compound 16b demonstrated significant inhibitory potency against FLT3-ITD (IC50 = 5.60 nM) and better antiproliferative activity than quizartinib against MV4-11 cell line (IC50 = 0.176 nM). It is indicated that compound 16b for the treatment of acute myeloid leukemia could be very promising.

SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES

The present invention relates to substituted N-heterocyclyl- and N-heteroaryltetrahydropyrimidinones of the general formula (I) or salts thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to

Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion

The receptor tyrosine kinase FLT-3 is frequently mutated in acute myeloid leukemia; however, current small molecule inhibitors suffer from limited efficacy in the clinic. Conversion of a FLT-3 inhibitor (quizartinib) into a proteolysis targeting chimera (

KINASE INHIBITORS

There are provided compounds of formula I, wherein T, A, Q, Z, G, R4, R5a, R5b and n have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members

HERBICIDAL MIXTURES

The present invention provides a composition comprising (A) a compound of formula (I): wherein R1 is methyl or methoxy, R2 is hydrogen, methyl or ethoxy and A is a substituted heteroaryl group, or an N-oxide or salt form thereof, and